Key result
Oral glucose tolerance testing in CAD patients without known diabetes identified 26.9% with diabetes and 37.3% with IGR, increasing overall diagnosed diabetes from 32.8% to 52.9%.
Why the study?
The glucometabolic state of patients with CAD in China needed characterization.
Does oral glucose tolerance testing improve the detection of abnormal glucose regulation compared to fasting plasma glucose testing alone in patients hospitalized for coronary artery disease in China?
Cross-Sectional (n=3,513)
Yes
Does oral glucose tolerance testing improve the detection of abnormal glucose regulation compared to fasting plasma glucose testing alone in patients hospitalized for coronary artery disease in China?
Answers are grounded in this paper and cite their sources.
Abnormal glucose regulation is highly prevalent in Chinese patients hospitalized with coronary artery disease and is substantially underestimated by fasting plasma glucose testing alone, supporting routine use of oral glucose tolerance testing.
AIM: The aim of this article is to characterize the glucometabolic state of patients with coronary artery disease (CAD) in China. METHODS AND RESULTS: This multicentre study recruited 3513 patients hospitalized for CAD, of whom 35.1% were admissions for acute CAD and 64.9% were elective admissions for CAD. At entry, 1153 patients had known type 2 diabetes and 97 had newly diagnosed diabetes [fasting plasma glucose level (FPG) > or =7.0 mmol/L]. Oral glucose tolerance tests (OGTTs) performed in the remaining patients revealed that 26.9% had diabetes and 37.3% had impaired glucose regulation (IGR). The prevalence of abnormal glucose regulation (AGR) was similar in the acute and elective admissions groups. Overall, the proportion of patients with diagnosed diabetes increased from 32.8% at baseline to 52.9% post-OGTT analysis. In total, 87.4% of patients with IGR and 80.5% of patients with diabetes would have remained undiagnosed if OGTTs had not been performed. CONCLUSION: AGR is common in patients with CAD. The prevalence of AGR is underestimated by FPG testing alone. OGTTs should be routinely used to assess the glucometabolic state of patients with CAD. Individuals identified with IGR or type 2 diabetes should receive treatment to reduce the progression of AGR and associated complications.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2006) conducted a cross-sectional in Coronary artery disease (n=3,513). Oral glucose tolerance test (OGTT) vs. Fasting plasma glucose (FPG) testing alone was evaluated on Proportion of patients with diagnosed diabetes. Oral glucose tolerance testing in CAD patients without known diabetes identified 26.9% with diabetes and 37.3% with IGR, increasing overall diagnosed diabetes from 32.8% to 52.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: